IDEXX Laboratories (IDXX) News Today

IDEXX Laboratories, Inc. (NASDAQ:IDXX) shares are trading higher as strong quarterly results, raised guidance, and multiple analyst upgrades have boosted investor confidence.

• Positive Sentiment: Earnings beat by $0.35 EPS ($3.63 vs. $3.28), driving upside momentum. Earnings Results
• Positive Sentiment: Shares gapped up on the strong Q2 report. Shares Gap Up
• Positive Sentiment: Reached a new 52-week high following earnings. New 52-Week High
• Positive Sentiment: Updated FY2025 guidance to $12.40–12.76 EPS (above consensus) and $4.2–4.3 billion in revenue. Guidance Update
• Positive Sentiment: Leerink Partners raised Q3 EPS to $3.18 and lifted FY25–FY28 EPS projections. Free Report
• Positive Sentiment: BTIG Research boosted its price target from $545 to $785 and maintained a buy rating. BTIG Research
• Positive Sentiment: Morgan Stanley raised its price target to $722 from $626. Morgan Stanley
• Positive Sentiment: JPMorgan Chase lifted its objective to $675, kept an overweight rating, and forecasts strong price appreciation. JPMorgan JPMorgan Forecast
• Positive Sentiment: Analysts hold a consensus “Moderate Buy” rating on the stock. Consensus Rating
• Neutral Sentiment: Zacks names IDEXX a top momentum stock for the long term. Momentum Stock
• Neutral Sentiment: Featured by MarketBeat as one of the best water stocks to consider. Water Stocks
• Neutral Sentiment: Earned a 93 RS rating for market leadership. 93 RS Rating
• Neutral Sentiment: Received a composite rating upgrade in recent screenings. Composite Rating
• Neutral Sentiment: Analysts debate if the 28% stock surge on the pet-healthcare boom leaves further upside. Too Late to Buy?
• Neutral Sentiment: Five analysts shared varied outlooks on IDEXX’s next phase. Analyst Commentary